"DLA Piper Advises TD Cowen on $30 Million Public Offering for Jasper Therapeutics"

"DLA Piper advised TD Cowen in a $30 million public offering for Jasper Therapeutics, a biotechnology company developing briquilimab, an antibody therapy for mast cell-driven diseases like chronic urticaria and asthma. The advisory team was led by partner Stephen Alicanti and included several other partners and associates from various locations."

DLA Piper served as legal counsel to TD Cowen, acting as the sole book-running manager in a public offering transaction for Jasper Therapeutics, Inc. The transaction involved a US$30 million public offering of common stock, pre-funded warrants, and common warrants for Jasper Therapeutics, a clinical-stage biotechnology company focused on developing briquilimab, a novel antibody therapy targeting KIT (CD117) to treat mast cell-driven diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma. The legal team from DLA Piper was led by Partner Stephen Alicanti from New York, and included Partners Lisa Haile from San Diego and Christopher Mikson from Philadelphia, Of Counsel Christie Lehr from Raleigh, and Associates Gina Lee and Alexander Grynszpan from Raleigh, as well as Angie Franco from New York.

"DLA Piper Advises TD Cowen on $30 Million Public Offering for Jasper Therapeutics"

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads